Histologically Overt Stromal Response and the Risk of Progression after Radical Prostatectomy for Prostate Cancer

Mutlay Sayan; Yetkin Tuac; Samet Kucukcolak; Mary D. Rowan; Grace K. Pratt; Cagdas Aktan; Elza Tjio; Dilara Akbulut; Shalini Moningi; Jonathan E. Leeman; Peter F. Orio; Paul L. Nguyen; Anthony V. D’Amico; Mahmut Akgul

doi:10.3390/cancers16101871

Cancers (May 2024)

Histologically Overt Stromal Response and the Risk of Progression after Radical Prostatectomy for Prostate Cancer

Mutlay Sayan,
Yetkin Tuac,
Samet Kucukcolak,
Mary D. Rowan,
Grace K. Pratt,
Cagdas Aktan,
Elza Tjio,
Dilara Akbulut,
Shalini Moningi,
Jonathan E. Leeman,
Peter F. Orio,
Paul L. Nguyen,
Anthony V. D’Amico,
Mahmut Akgul

Affiliations

Mutlay Sayan: Department of Radiation Oncology, Brigham and Women’s Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
Yetkin Tuac: Department of Statistics, Ankara University, 06100 Ankara, Türkiye
Samet Kucukcolak: Department of Pathology and Laboratory Medicine, Rutgers University, New Brunswick, NJ 07102, USA
Mary D. Rowan: Department of Radiation Oncology, Brigham and Women’s Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
Grace K. Pratt: Department of Radiation Oncology, Brigham and Women’s Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
Cagdas Aktan: Department of Medical Biology, Faculty of Medicine, Bandirma Onyedi Eylul University, 10250 Balikesir, Türkiye
Elza Tjio: Histopathology Department, Harrogate District Hospital, Harrogate HG2 7SX, UK
Dilara Akbulut: Laboratory of Pathology, Center for Cancer Research, National Institutes of Health, Bethesda, MD 20892, USA
Shalini Moningi: Department of Radiation Oncology, Brigham and Women’s Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
Jonathan E. Leeman: Department of Radiation Oncology, Brigham and Women’s Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
Peter F. Orio: Department of Radiation Oncology, Brigham and Women’s Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
Paul L. Nguyen: Department of Radiation Oncology, Brigham and Women’s Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
Anthony V. D’Amico: Department of Radiation Oncology, Brigham and Women’s Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
Mahmut Akgul: Department of Pathology and Laboratory Medicine, Albany Medical Center, Albany, NY 12208, USA

DOI: https://doi.org/10.3390/cancers16101871
Journal volume & issue: Vol. 16, no. 10
p. 1871

Abstract

Read online

Purpose: Given the variable clinical course of prostate cancer and the limitations of current prognostic factors, this study was conducted to investigate the impact of a histologically overt stromal response (HOST-response) to prostate cancer on clinical outcomes after radical prostatectomy. Methods: This retrospective analysis utilized The Cancer Genome Atlas (TCGA) to evaluate data from individuals with a confirmed diagnosis of prostate cancer who underwent radical prostatectomy and had available pathology slides. These slides were assessed for the presence of a HOST-response, similar to desmoplasia. The primary endpoint was progression-free survival (PFS). A multivariable competing risk regression analysis was used to assess whether a significant association existed between HOST-response and PFS, adjusting for known prostate cancer prognostic factors. Results: Among the 348 patients analyzed, 166 (47.70%) demonstrated a HOST-response. After a median follow-up of 37.87 months (IQR: 21.20, 65.50), the presence of a HOST-response was significantly associated with a shorter PFS (SDHR, 2.10; 95% CI, 1.26 to 3.50; p = 0.004), after adjusting for covariates. Conclusions: HOST-response in prostate cancer patients treated with radical prostatectomy is significantly associated with reduced PFS, suggesting a potential benefit from adjuvant therapy and highlighting the need for further investigation in a prospective randomized clinical trial.

Published in Cancers

ISSN: 2072-6694 (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.mdpi.com/journal/cancers/

About the journal

Abstract

Keywords